2. Search Result
Search Result
Results for "

MSSA ATCC 29213

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

7

Peptides

5

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100180
    Delpazolid
    1 Publications Verification

    LCB01-0371

    		 Bacterial Antibiotic Infection
    Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of MSSA and MRSA with a MIC90 of 2 μg/mL for both of them.
    Delpazolid
  • HY-B2234
    Povidone iodine
    2 Publications Verification

    iodopovidone

    		 Environmental Pollutants Bacterial Infection
    Povidone iodine (iodopovidone) displays excellent antibacterial activity which can against MRSA and MSSA strains with MICs of 31.25 mg/L and 7.82 mg/L, respectively.
    Povidone iodine
  • HY-133119
    PK150

    		Bacterial Infection
    PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 μM, respectively .
    PK150
  • HY-18702
    Targocil

    		Bacterial Infection
    Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
    Targocil
  • HY-14926
    Levonadifloxacin

    (S)-(-)-Nadifloxacin; WCK 771

    		 Antibiotic Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin
  • HY-14956
    Nemonoxacin
    1 Publications Verification

    TG-873870

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin
  • HY-103645
    GW779439X
    1 Publications Verification

    		 Bacterial Aurora Kinase Apoptosis Infection Cancer
    GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
    GW779439X
  • HY-150331
    DNA ligase-IN-2

    		DNA/RNA Synthesis Bacterial Infection
    DNA ligase-IN-2 (compound 2) is a potent LigA inhibitor and inhibits the DNA-independent autoadenylation activity of both full-length LigA and a truncated enzyme, LigA:AD (IC50=29 nM). DNA ligase-IN-2 effectively inhibits the growth of Staphylococcus aureus in vitro, with MIC valuse of 1, 1, and >64 μg/mL for S. aureus ATCC 29213, S. aureus ATCC 700699 and E. coli ATCC 25922, respectively .
    DNA ligase-IN-2
  • HY-178949
    MRSA antibiotic 3

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
    MRSA antibiotic 3
  • HY-146330
    FtsZ-IN-2

    		Bacterial Infection
    FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .
    FtsZ-IN-2
  • HY-147960
    Glycosyltransferase-IN-1

    		Glycosyltransferase Infection
    Glycosyltransferase-IN-1 (compound 5m) is a potent glycosyltransferase inhibitor, with an IC50 of 82.8 μM. Glycosyltransferase-IN-1 shows antibacterial activity, with MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli .
    Glycosyltransferase-IN-1
  • HY-164051
    1650-M15
    1 Publications Verification

    		 Bacterial Infection
    1650-M15 is an inhibitor of lipoteichoic acid synthase (LtaS). It has inhibitory activity against Gram-positive bacteria but has no significant inhibitory effect against Gram-negative bacteria. The IC50s of 1650-M15 against MRSA and MSSA are 62.44 μM and 66.42 μM, respectively, and the MICs are both 200 μM .
    1650-M15
  • HY-P5206
    Garvicin KS, GakB

    		Bacterial Infection
    Garvicin KS, GakB is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakC. Garvicin KS, GakB inhibits fibroblast viability and proliferation. Garvicin KS, GakB with GakA, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakB
  • HY-P5205
    Garvicin KS, GakA

    		Bacterial Infection
    Garvicin KS, GakA is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakB, and GakC. Garvicin KS, GakA inhibits fibroblast viability and proliferation. Garvicin KS, GakA with GakB, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakA
  • HY-147546
    Antibacterial agent 107

    		Bacterial Infection
    Antibacterial agent 107 (compound 14) is a potent antibacterial agent. Antibacterial agent 107 shows potent antibacterial activity against Gram-positive bacteria, with a MIC of 1.56 μg/mL (MRSA). Antibacterial agent 107 exhibits low hemolytic activity, high membrane selectivity, and rapid bactericidal activity. Antibacterial agent 107 shows effective in vivo efficacy in the murine model of bacterial keratitis caused by Staphylococcus aureus ATCC29213 .
    Antibacterial agent 107
  • HY-169571
    Antimicrobial agent-38

    		Bacterial Infection
    Antimicrobial agent-38 (compound 10) is a potent inhibitor of methicillin-resistant S. aureus strain ATCC 700699 and nonresistant strain ATCC 29213, with MICs of 32 and 64 mg/L .
    Antimicrobial agent-38
  • HY-P5638
    FLGFVGQALNALLGKL-NH2

    		Bacterial Infection
    FLGFVGQALNALLGKL-NH2 is an antimicrobial peptide of frog origin. FLGFVGQALNALLGKL-NH2 has activity against Staphylococcus aureus ATCC 29213 (MIC=32 μM) .
    FLGFVGQALNALLGKL-NH2
  • HY-142097
    Glicophenone

    		Bacterial Infection
    Glicophenone is an antibacterial agent with MICs of both 32 μg/mL against MRSA OM481, MRSA OM505, MRSA OM584, MRSA OM623 and MSSA 209P .
    Glicophenone
  • HY-168486
    Biotin protein ligase-IN-1

    		Bacterial Infection
    Biotin protein ligase-IN-1 (Compound Bio-9) is an inhibitor of biotin protein ligase (BPL) with a Kd value of 7 nM. Biotin protein ligase-IN-1 exhibits antibacterial activity, with MIC values of 0.2 and 20 μM against Staphylococcus aureus (including MRSA and MSSA) and Mycobacterium tuberculosis, respectively .
    Biotin protein ligase-IN-1
  • HY-108021
    HT-61

    		Bacterial Infection
    HT-61 is a quinolone antibacterial agent. HT-61 exhibits bactericidal activity against gram-positive bacteria including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). HT-61 can enhance the effect of Tobramycin (HY-B0441) against Pseudomonas aeruginosa .
    HT-61
  • HY-175723
    MAO-A/B-IN-4

    		Bacterial Monoamine Oxidase Infection
    MAO-A/B-IN-4 is an orally active MAO-A/B inhibitor, with IC50 values of 51.3 μM and 47.0 μM, respectively. MAO-A/B-IN-4 exhibits potent activity against S. aureus, MSSA, MRSA, LRSA, and LREFa. MAO-A/B-IN-4 demonstrates potent antibacterial efficacy in a mouse model of LRSA peritonitis infection. MAO-A/B-IN-4 can be used for the study of bacterial infections .
    MAO-A/B-IN-4
  • HY-P3349
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]

    		Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]
  • HY-P3348
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]

    		Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]
  • HY-125424
    AM8191 hydrochloride

    		Bacterial Inflammation/Immunology
    AM8191 is an orally active bactericidal and selectively inhibits DNA synthesis and Staphylococcus aureus gyrase (IC50=1.02 μM) and topo IV (IC50=10.4 μM). AM8191 inhibits S. aureus MSSA (MIC=0.02 μg/mL) and S. aureus MRSA (MIC=0.06 μg/mL) .
    AM8191 hydrochloride
  • HY-161827
    Anti-MRSA agent 14

    		Bacterial Infection
    Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively .
    Anti-MRSA agent 14
  • HY-122008
    ORM-3819

    		Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1.
    ORM-3819
  • HY-14926B
    Levonadifloxacin arginine

    (S)-(-)-Nadifloxacin arginine; WCK 771 arginine

    		 Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1 cells .
    Levonadifloxacin arginine
  • HY-179059
    Anti-MRSA agent 40

    		Bacterial Reactive Oxygen Species (ROS) Infection
    Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
    Anti-MRSA agent 40
  • HY-150983
    ATP synthase inhibitor 2

    		ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2
  • HY-150983A
    ATP synthase inhibitor 2 TFA

    		ATP Synthase Bacterial Infection
    ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
    ATP synthase inhibitor 2 TFA
  • HY-163762
    Antibacterial agent 226

    		Bacterial Infection
    Antibacterial agent 226 (Compound 7f) is an antibacterial agent, that inhibits Staphylococcus aureus strains and methicillin-resistant S. aureus strain with MIC of 2 μg/mL. Antibacterial agent 226 exhibits cytotoxicity to HEK293 with IC50 of 1.9 μM .
    Antibacterial agent 226
  • HY-151937
    Antibacterial agent 127

    		Bacterial Infection
    Antibacterial agent 127 (Compound 23) is a potent antibacterial agent .
    Antibacterial agent 127
  • HY-14926A
    Levonadifloxacin arginine hydrate

    (S)-(-)-Nadifloxacin arginine hydrate; WCK-771A arginine hydrate

    		 Antibiotic Bacterial Infection
    Levonadifloxacin (arginine) hydrate is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin (arginine) hydrate shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin arginine hydrate
  • HY-P5207
    Garvicin KS, GakC

    		Bacterial Infection
    Garvicin KS, GakC is a peptide at sizes of 32 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakB. Garvicin KS, GakC inhibits fibroblast viability and proliferation. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .
    Garvicin KS, GakC
  • HY-14926R
    Levonadifloxacin (Standard)

    (S)-(-)-Nadifloxacin (Standard); WCK 771 (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Levonadifloxacin (Standard) is the analytical standard of Levonadifloxacin. This product is intended for research and analytical applications. Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin (Standard)
  • HY-172390
    Florfenicol-propanoate-piperidin

    		Bacterial Infection
    Florfenicol-propanoate-piperidin (Compound 1) is the derivative of Florfenicol (HY-B1374). Florfenicol-propanoate-piperidin exhibits antibacterial activity, inhibits E. coli ATCC25922, Salmonella CICC110420, S. aureus ATCC29213, B. subtilis CMCC(B)63501, E. faecalis ATCC29212, S. suis CVCC606, and Haemophilus parasuis with MIC of 2-8 μM .
    Florfenicol-propanoate-piperidin
  • HY-125533
    TXA497

    		Bacterial Infection
    TXA497 is a potent local topical bactericide. TXA497 exerts its bactericidal effect by interfering with the polymerization kinetics of the bacterial cell division protein FtsZ, rather than inhibiting it. TXA497 shows strong activity against various Staphylococcus aureus strains, including MRSA and MSSA, with an MIC value ranging from 1.0 to 2.0 μg/mL. TXA497 skin deposition is concentration-dependent in its formulation, consistent with Fick's first law. TXA497 has limited systemic permeability through the lipid pathway of the stratum corneum and is easily absorbed through this route. TXA497 can be used for research on topical bactericidal agents .
    TXA497
  • HY-151458
    VEGFR-2/DHFR-IN-1

    		VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal Infection Cancer
    VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of VEGFR-2 and DHFR with IC50s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC50 values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer .
    VEGFR-2/DHFR-IN-1
  • HY-N16443
    Sporminarin A

    		Endogenous Metabolite Fungal Bacterial Infection
    Sporminarin A (Compound 1), a polyketide, is a microbial secondary metabolite. Sporminarin A can be isolated from the Sporormiella minimoides. Sporminarin A has significant antifungal activity against Aspergillus flavus with an MIC50 of 25  μg/mL. Sporminarin A also has antibacterial activity against Staphylococcus aureus (ATCC 29213) and Candida albicans (ATCC 14053) .
    Sporminarin A
  • HY-175987
    Antimycobacterial agent-12

    		Bacterial Infection
    Antimycobacterial agent-12 (Compound Ec42), a derivative of Platensimycin (HY-127146), is a dual-functional inhibitor KasA and KasB. Antimycobacterial agent-12 has antibacterial activity with a MICs of 2, 2 and 4 μg/mL against Staphylococcus aureus ATCC 29213, Mycobacterium smegmatis and its Isoniazid (HY-B0329)-resistant strain, respectively. Antimycobacterial agent-12 has a superior antimycobacterial activity in M. smegmatis-infected mouse models. Antimycobacterial agent-12 can be used for tuberculosis research .
    Antimycobacterial agent-12
  • HY-168729
    Antibacterial agent 256

    		Bacterial Infection
    Antibacterial agent 256 (Compound C09) is an inhibitor for type I signal peptidase (SPase I). Antibacterial agent 256 inhibits gram-positive bacteria, that inhibits S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1 and S. suis P1/7, with MIC of 1-16 μg/mL. Antibacterial agent 256 exhibits cytotoxicity in cancer cell HEp-2 and Caco-2 with CC50 of 14.65 μg/mL and 21.93 μg/mL. Antibacterial agent 256 exhibits a hemolytic activity on mouse RBCs, with an HC50 of 13.29 μg/mL. Antibacterial agent 256 ameliorates the MRSA skin infection in mouse model .
    Antibacterial agent 256
  • HY-N16526
    Juncatrin B

    		Bacterial Infection
    Juncatrin B is a type of dihydrophenanthrene compound. Juncatrin B exhibits inhibitory activity against both Methicillin (HY-121544)-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA). Juncatrin B can inhibit the formation of biofilms in MSSA and MRSA. Juncatrin B has no significant activity against Gram-negative bacteria. Juncatrin B can be used in the research of anti-Staphylococcus aureus .
    Juncatrin B
  • HY-103645R
    GW779439X (Standard)

    		Reference Standards Bacterial Aurora Kinase Apoptosis Infection Cancer
    GW779439X (Standard) is the analytical standard of GW779439X (HY-103645). This product is intended for research and analytical applications. GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase Stk1. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive. GW779439X is an AURKA inhibitor and induces apoptosis by the caspases 3/7 pathway . MRSA:methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus
    GW779439X (Standard)
  • HY-180767
    Azithromycin-amide-C3-amide-quinoxaline

    		Drug Derivative Bacterial Topoisomerase Infection Cancer
    Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is an Azithromycin (HY-17506) derivative and antibacterial agent. Azithromycin-amide-C3-amide-quinoxaline inhibits topoisoisomerase I with an IC50 of 120.7 μM. Azithromycin-amide-C3-amide-quinoxaline interacts with 70S E. coli ribosome with a Kd of 0.8 nM. Azithromycin-amide-C3-amide-quinoxaline inhibits bacterial translation with an IC50 of 0.7 μM. Azithromycin-amide-C3-amide-quinoxaline shows antibacterial potency against S. pneumonia ATCC 49619, S. aureus ATCC 29213, E. faecalis ATCC 29212 with MICs of 0.06 μg/mL, 2 μg/mL, 0.5 μg/mL, respectively. Azithromycin-amide-C3-amide-quinoxaline exhibits anticancer activity against prostate cancer, colon cancer .
    Azithromycin-amide-C3-amide-quinoxaline
  • HY-N16702
    8-Demethyleucalyptin

    		Drug Derivative Others
    8-Demethyleucalyptin is a natural flavonoid.
    8-Demethyleucalyptin
  • HY-P11622
    Gramicidin S analogue 9

    		Drug Derivative Infection
    Gramicidin S analogue 9 is a bactericidal agent that can be found as a cyclic peptide analogue. Gramicidin S analogue 9 disrupts bacterial cell membranes. Gramicidin S analogue 9 can be used for the research of methicillin-resistant staphylococcus aureus infection .
    Gramicidin S analogue 9
  • HY-185443
    UCP1172

    		Bacterial Dihydrofolate reductase (DHFR) Infection
    UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
    UCP1172
  • HY-182461
    Deoxymorellin

    		Bacterial Infection
    Deoxymorellin is a caged xanthone found in resins and fruits of Garcinia hanburyi hook. f.. Deoxymorellin exhibits cytotoxicity. Deoxymorellin can be used for research of Methicillin (HY-121544)-resistant or Methicillin-susceptible Staphylococcus aureus .
    Deoxymorellin
  • HY-182022
    ZLWH-67

    		Bacterial Reactive Oxygen Species (ROS) Drug Derivative DNA/RNA Synthesis Infection
    ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models .
    ZLWH-67

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: